MAL and adenocarcinoma: Silencing of MAL via its promoter methylation contributes to the transformation and oncogenesis of HPV-infected cervical cells, suggesting MAL methylation as a diagnostic biomarker for squamous cell carcinoma (SCC) and adenocarcinoma (AdCA), as well as their precancerous lesions (68).